Gilead Stock Earnings: What to Watch

When Gilead reports earnings, here's what you should keep an eye on.

Michael Douglass
Michael Douglass and Dave Williamson
Jul 16, 2014 at 5:00PM
Health Care

Gilead Sciences (NASDAQ:GILD) has had a great year so far, with Sovaldi (its hepatitis c cure) turning in an incredible $2.3 billion in sales in its first full quarter on the market. Sovaldi's performance has helped fuel Gilead's 18% price gain year-to-date.

So it's no surprise that investors should be watching for Sovaldi sales when Gilead announces earnings later this month. But in the video below, health care analysts Michael Douglass and David Williamson lay out the company's other long-term opportunities and how they matter for Gilead.